Growth Metrics

Vivos Therapeutics (VVOS) Total Debt (2019 - 2026)

Vivos Therapeutics (VVOS) reported Total Debt of $7.7 million for Q1 2026, down 12.53% on a QoQ basis from $8.8 million in Q4 2025.

Vivos Therapeutics (VVOS) has 5 years of Total Debt data on file, last reported at $7.7 million in Q1 2026.

  • Quarterly Total Debt changed N/A year-over-year to $7.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.7 million (changed N/A YoY) and the FY2025 annual result came in at $8.8 million, changed N/A from the prior year.
  • Total Debt eased to $7.7 million in Q1 2026 per VVOS's latest filing, from $8.8 million in the prior quarter.
  • Across five years, Total Debt topped out at $8.8 million in Q4 2025 and bottomed at $7.7 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 34.05 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 14.72 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 28.07 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 11.03 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 598.50 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 8.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 10.13 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 1.93 Bn
10 Vivos Therapeutics 9.87 Mn 7.64 Mn 3.06 Mn 7.72 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 7.72 Mn
Dec 31, 2025 8.82 Mn
Sep 30, 2025 8.72 Mn
Jun 30, 2025 7.92 Mn
Dec 31, 2021 1.27 Mn
Sep 30, 2021 1.27 Mn
Jun 30, 2021 1.27 Mn
Mar 31, 2021 1.27 Mn
Dec 31, 2020 1.29 Mn
Dec 31, 2019 3.71 Mn